VTRS

Dopo l'orario di chiusura: 11.30

Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1174)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Confronta VTRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	11.30	13.49B	15.05B	-883.30M	1.89B	-0.74
ZTS Zoetis Inc	165.89	74.84B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.24	41.78B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	12.92	40.96B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.92	24.83B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	143.26	14.50B	2.24B	385.90M	440.10M	3.73

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Confronta VTRS con altri titoli

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com

Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights

Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN

Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch

Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com

Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance

Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post

Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart

Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.

Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey

Viatris Enters Oversold Territory - Nasdaq

Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN

Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail

Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Another Disappointing Drug Import Alert from India - The People's Pharmacy

When (VTRS) Moves Investors should Listen - Stock Traders Daily

US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times

Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR

Viatris Inc. stock falls Monday, underperforms market - MarketWatch

Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha

FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma

Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com

Viatris Inc. stock falls Monday, still outperforms market - MarketWatch

Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News

Viatris Inc. stock falls Friday, still outperforms market - MarketWatch

Viatris Stock: Is VTRS Outperforming The Healthcare Sector? - Barchart

Viatris receives FDA warning letter for 11 drugs made at India plant - MSN

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris faces FDA import restrictions at Indian facility - The Pharma Letter

Viatris confirms receipt of warning letter, import alert for India facility - TipRanks

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - Kilgore News Herald

US FDA restricts imports of some Viatris drugs made at India facility - Reuters

FDA restricts import of certain Viatris products due to plant violations - Investing.com UK

Viatris says India plant hit with FDA warning letter, import ban on 11 products - FiercePharma

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve

Cenerimod shows promise in SLE trial, Viatris reports - Investing.com

Viatris announces publication of CARE study results - TipRanks

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VTRS